American Society of Hirudotherapy

Symbiosis of Aeromonas veronii biovar sobria and Hirudo medicinalis, the medicinal leech: a novel model for digestive tract associations

Biology paper published in Infection and Immunity (1999)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSafety & Infection ControlGenomics & ProteomicsGraf J · Infection and Immunity, 1999

Abstract

Hirudo medicinalis, the medicinal leech, is applied postoperatively in modern medicine. Infections by Aeromonas occur in up to 20% of patients unless a preemptive antibiotic treatment is administered. The associated infections demonstrate the need for a better understanding of the digestive tract flora of H. medicinalis. Early studies reported the presence of a single bacterial species in the digestive tract and suggested that these bacteria were endosymbionts contributing to the digestion of blood. In this study, we cultivated bacteria from the digestive tract and characterized them biochemically. The biochemical test results identified the isolates as Aeromonas veronii biovar sobria. This species identification was supported by sequence comparison of a variable region of the genes coding for 16S rRNA. In a colonization assay, a rifampin-resistant derivative of a symbiotic isolate was fed in a blood meal to H. medicinalis. The strain colonized the digestive tract rapidly and reached a concentration similar to that of the native bacterial flora. For the first 12 h, the in vivo doubling time was 1.2 h at 23 degreesC. After 12 h, at a density of 5 x 10(7) CFU/ml, the increase in viable counts ceased, suggesting a dramatic reduction in the bacterial growth rate. Two human fecal isolates, identified as Aeromonas hydrophila and A. veronii biovar sobria, were also able to colonize the digestive tract. These data demonstrate that the main culturable bacterium in the crop of H. medicinalis is A. veronii biovar sobria and that the medicinal leech can be used as a model for digestive tract association of Aeromonas species.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAeromonasAnimalsColony Count, MicrobialDNA, RibosomalDigestive SystemFecesHumansKineticsLeechesMolecular Sequence DataRNA, Ribosomal, 16SSymbiosis

Summary

Classical paper establishing Aeromonas veronii biovar sobria (not A. hydrophila) as the predominant culturable symbiont of Hirudo medicinalis crop, with characterization of colonization kinetics in a leech model of digestive tract symbiosis.

Why This Matters for Hirudotherapy

What the study examined: Graf cultured and biochemically characterized the dominant bacterium in the digestive tract (crop) of the medicinal leech Hirudo medicinalis, identifying it as Aeromonas veronii biovar sobria (supported by sequence comparison of a variable region of the 16S rRNA genes), and showed in a colonization assay that a rifampin-resistant derivative of a symbiotic isolate, fed in a blood meal, rapidly colonized the digestive tract and reached a concentration similar to the native bacterial flora. The abstract notes that Aeromonas infections occur in up to 20% of patients unless preemptive antibiotic treatment is administered. Why it matters for hirudotherapy: this work establishes the microbiological basis for the single most important infectious risk of medicinal leech therapy, supporting the standard practice of prophylactic antibiotic coverage when leeches are applied, and it defines the leech as a model for digestive-tract association of Aeromonas species. Caveat: this is a preclinical microbiology and colonization study in the leech itself, not a clinical trial of patient infection or antibiotic prophylaxis, so the 'up to 20%' figure is cited background rather than an outcome measured here.

Citation

Symbiosis of Aeromonas veronii biovar sobria and Hirudo medicinalis, the medicinal leech: a novel model for digestive tract associations.

Graf J · Infection and Immunity, 1999

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.